EVQLV CEO, Andrew Satz, recently joined the Amplifying Scientific Innovation podcast with Dr. Sophia Ononye-Onyia. They discussed his definition of scientific innovation, personal anecdotes of his CEO journey and EVQLV’s unique approach to scientific innovation through the acceleration of biologic therapies with the power of artificial intelligence (A.I.). Watch their discussion below or on Dr. Sophia’s website.
Andrew Satz on the ‘Amplifying Scientific Innovation’ Podcast with Dr. Sophia Ononye-Onyia
Jul 17, 2020 | Blog | 0 comments
Daniel Gigante
← How Our Algorithm Models the Drug Discovery Process
EVQLV, Manhattan BioSolutions Enter Strategic Collaboration to Discover Novel Antibody Therapies →
‘Life Science Leader’ publishes EVQLV CEO’s Guide for “Demystifying AI”
by EVQLV | May 13, 2022 | Blog, News | 0 Comments
Examining AI as automated, assistive, analytical, accelerated, or augmented intelligence is a framework for thinking about how to apply these tools to data in ways that are aligned with an organization’s goals. This framework is designed to allow those who do not routinely build or employ AI to avoid the overhyped rhetoric of AI and consider the practical outcomes of employing it.
EVQLV, Manhattan BioSolutions Announce UB CAT Grant Award
by EVQLV | June 29, 2021 | Press Releases | 0 Comments
University at Buffalo Center for Advanced Technology in Big Data and Health Sciences New York City, New York Jun 29, 2021 (Issuewire.com) - EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, and...
NY Bio-Computation Startup EVQLV Closes Financing Round
by Alexander Sonneborn | February 8, 2021 | Press Releases | 0 Comments
NEW YORK, February 8, 2021 -- EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, today announced the closing of a funding round that will be used to advance the company’s R&D efforts, boost development...
EVQLV Welcomes Operations & Finance Lead Alexander Sonneborn
by EVQLV | February 1, 2021 | News | 0 Comments
NEW YORK, February 1, 2021 -- EVQLV is pleased to announce that Alexander Sonneborn has joined EVQLV to oversee company operations and finances. After an early career in the life sciences, Alexander transitioned to entrepreneurial activities in technology-based...
EVQLV Submits 1 Million Ab Initio Derived Sequences for Validation
by Alexander Sonneborn | January 12, 2021 | Press Releases | 0 Comments
NEW YORK, January 12, 2021 - EVQLV has submitted one million AI-generated sequences for independent laboratory validation in fulfillment of the second phase of a project with its collaborator. The first phase of the project consisted of 100 antibody sequences based...
0 Comments